GlucoTrack to present first-in-human study for CBGM at 2025 conference on ATTD

people with diabetes announced that safety and performance data from its first-in-human trial of its long-term continuous blood glucose monitoring, CBGM, system will be presented at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes, ATTD. “We are pleased to be showcasing these significant results from our first-in-human trial, demonstrating the safety, feasibility and promising performance of our CBGM,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack (GCTK). “This ground-breaking study supports our approach to measuring glucose directly from the blood, rather than interstitial fluid, which enables real-time glucose monitoring with potentially greater accuracy and without on-body wearables, representing a potentially transformative advancement in diabetes management. We look forward to sharing detailed findings from this important study at ATTD and advancing our clinical program with our upcoming chronic implant study.”